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Abstract
Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients,
histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of
change in treatment, response, and outcome of FL patients at our institution over the last four decades. Seven
hundred and twenty-seven patients (389 F/338 M; median age, 57 years) consecutively diagnosed with grade 1-3a FL
between 1980 and 2017, categorized into four decades according to the time of diagnosis, constituted the study
population. Clinical characteristics, treatment, response, absolute and relative survival, HT, second malignancies (SM),
and causes of death were assessed. Median OS for the entire cohort was 17.6 years. From decade 1 to 4, there was an
increase in the complete response rate (48 to 70%), progression-free survival (40 to 56% at 5 years), OS (77 to 86% at
5 years), and relative survival ratio (0.83 to 0.94 at 5 years), with no significant differences in the risk of HT or SM.
Lymphoma remained the most common cause of death in all four decades. These findings illustrate the overall
improvement in outcome for FL patients, but support the need for further research into risk stratification and
management.
Introduction
Follicular lymphoma (FL), the most common type of
indolent B-cell lymphoma1, is characterized by a long
survival, despite a pattern of continuous relapses during
follow-up2, and shorter duration of responses in each
relapse3. Although data initially indicated that survival of
FL patients had remained unchanged during the last three
decades of the 20th century4, more recent analyses have
acknowledged that improvements in therapy, most likely
related to the use of rituximab, as well as supportive
measures, may have contributed to a better progression-
free (PFS) and overall survival (OS) in recent years5–15.
Despite a median OS now approaching 20 years, early
progression (progression of disease within 24 months, or
POD24), defined as a relapse within the first 2 years of
frontline treatment, confers a much poorer prognosis16.
Likewise, histologic transformation (HT) to a high-grade
lymphoma significantly reduces survival17,18, although
recent studies have suggested that its incidence might be
lower in the rituximab era19. Some single-center and
registry studies have described the changes in survival of
FL patients over the last decades and trends in relative
survival according to the general population7,9. However,
to our knowledge, no single-center series has concurrently
examined the trends in observed and relative survival, the
risk of HT and second malignancies (SM), and the causes
of death over a long period of time.
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In this retrospective analysis of a single-center cohort,
we sought to describe the patterns of change in baseline
characteristics, treatment, response, PFS, absolute and
relative OS, risk of HT and SM, and causes of death of FL
patients over the last four decades at our institution.
Methods
Patients
Seven hundred and twenty-seven patients (389
females, 338 males; median age, 57 years) consecutively
diagnosed with grade 1-3a FL at Hospital Clínic of
Barcelona between January 1980 and December 2017
were included in the present study. All the available
diagnostic specimens (most of them dating from 1990
onwards) underwent pathological review. Patients with
grade 3b FL, primary gastrointestinal or cutaneous FL,
or composite lymphoma were excluded. Baseline patient
and disease characteristics, type of frontline treatment,
PFS and OS, and risk of HT and SM were assessed
retrospectively. Considering the time necessary for a
complete diagnosis and staging, frontline treatment was
defined as “immediate” if it was started within the first
2 months after diagnosis, or as a “watchful waiting”
policy if it was deferred for a longer period of time.
Treatment choices in each of the decades were in
accordance with the policies of our Department. During
decades 1 and 2, a “watchful waiting” strategy was
undertaken only in patients 65 years old or older, while
in decades 3 and 4, the initiation of treatment responded
to the GELF criteria20.
Since our study cohort spans a 38-year period, we
categorized patients into four groups according to the
decade of diagnosis: decade 1, 1980–1989; decade 2,
1990–1999; decade 3, 2000–2009; and decade 4,
2010–2017. We decided to include the last period in the
analyses, although, due to short follow-up, data con-
cerning survival and the risk of HT and SM should be
interpreted with caution. The study was conducted
according to the Hospital Clínic Institutional Review
Board and in accordance with the Declaration of Helsinki.
Response assessment and outcome
In most cases diagnosed during decades 1 and 2,
response to treatment was evaluated using only com-
puted tomography (CT). With the advent of positron
emission tomography (PET), PET-CT was increasingly
used as a staging and response assessment tool during
decades 3 and 4. Therefore, we use the term complete
response unconfirmed (CRu) when there was a residual
mass on the CT scan without fluorodeoxyglucose uptake
on the PET study. For response assessment purposes,
CR and CRu were considered equivalent. Definitions of
complete response (CR), partial response (PR), and
treatment failure were the standard21.
HT was defined based on histologic or cytological criteria.
It is challenging to affirm that second malignancies (SM)
are causally related to FL or its treatment (especially for
younger patients followed for a long period of time). We
define SM as all types of malignant tumors appearing after
the diagnosis of FL (including non-melanoma skin cancer).
Time from the diagnosis of FL to that of the second neo-
plasm was registered. In the event of the development of
more than one additional neoplasm in the same patient,
only the first one was considered for the analysis.
Since the definition of disease-related or unrelated
death might be a matter of discussion, we considered the
following causes of death: progressive FL, treatment-
related toxicities, neoplasms different from FL, and other/
unknown causes.
Statistical analysis
PFS was calculated from the date of the first dose of
frontline treatment to the date of progression (if a PR was
achieved after frontline treatment) or relapse (if a CR/CRu
was achieved after frontline treatment). Hence, early pro-
gressors (POD24) were defined as patients experiencing
progressive disease in the first 24 months after the initiation
of frontline treatment. This analysis only included patients
who received treatment and had a follow-up of more than
2 years. All patients were included for OS analysis, which was
calculated from the date of diagnosis to the date of last
follow-up or death from any cause. Kaplan-Meier survival
curves were plotted for the four decades and compared for
statistical differences by use of the log-rank test. To compare
the OS observed in our cohort with that of the general
population, patients were matched by age and sex with
Spanish individuals from the Human Mortality Database,
which accounts for other causes of death and provides an
estimate of the cause-specific survival through relative sur-
vival analysis (relsurv R package). The relative survival ratio
(RSR), calculated by dividing the observed survival of our
cohort by the expected survival of the general population,
was intended to reflect the reduction in life expectancy due
to lymphoma. To estimate the risk of HT and of SM, where
competitive events are possible, cumulative incidence was
calculated (cmprsk R package) and compared by use of
Gray’s test22. Likewise, when causes of death were evaluated
through cause-specific cumulative incidence of mortality,
competing risk of death was used. The χ2 test or p-exact test
were used for comparison of categorical variables among the
four decades. Nonparametric tests were used when neces-




Baseline characteristics of the 727 patients are shown in
Table 1. Patients were distributed according to the year of
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diagnosis: decade 1 (1980–1989), n= 79 (11%); decade 2
(1990–1999), n= 163 (22%); decade 3 (2000–2009),
n= 254 (35%); and decade 4 (2010–2017), n= 231 (32%).
Median follow-up for the entire series (calculated only for
surviving patients) was 7.6 years, and 31.8, 20.7, 12, and
3.2 years for decades 1–4, respectively. Most features did
not follow a significant trend over decades, except for the
more advanced age at diagnosis and better performance
status in decade 4 (P < 0.001).
Treatment and response to therapy
Initial treatment strategies given to patients in the entire
cohort and according to the decade of diagnosis are
depicted in Supplementary Table 1. Second- and third-
line treatments are detailed in Supplementary Tables 2
and 3. The proportion of patients who underwent an
initial “watchful waiting” strategy was 3%, 3%, 13%, and
30% for decades 1 to 4, respectively (P < 0.001), with a
median time of observation of 1.8 years (range,
3 months–9.3 years). Rituximab was part of the initial
treatment in none of the patients in decades 1 and 2, and
in 66 and 85% of patients in decades 3 and 4, respectively
(P < 0.001). Of the patients treated with chemoimmu-
notherapy during decades 3 and 4, 15 and 60% received
rituximab maintenance therapy, respectively. Cyclopho-
sphamide, doxorubicin, vincristine, and prednisone
(CHOP) were the most frequent frontline chemotherapy
regimen used in decades 1 and 2 (64 and 75% of patients,
respectively), while this regimen was only used in com-
bination with immunotherapy in decade 4. The advent of
the anti-CD20 antibody rituximab made its combination
with CHOP (R-CHOP) the preferred regimen in decades
3 and 4 (39 and 47%, respectively). Response to treatment
is detailed in Table 1. For the entire cohort, the percen-
tage of patients achieving a CR/CRu and a PR after
frontline treatment was 64 and 28%, respectively, while
8% of patients had refractory disease. A steady increase in
the rate of CR/CRu was seen, being of 48%, 53%, 73%, and
70% for decades 1–4, respectively, with the corresponding
decrease in the rate of PR and refractory cases. Interest-
ingly, cases not responding to frontline therapy decreased
from 10% in decade 1–4% in decade 4 (P < 0.001).
Risk of relapse/progression,
Data concerning PFS, POD24, OS, risk of HT, and risk
of SM are depicted in Table 2. Three hundred and sixty-
four patients (54%) were refractory or experienced
relapse/progression during follow-up, with a median PFS
for the entire cohort of 4.3 years, and a 10-year PFS of
34%. A significant increase in PFS was observed over the
decades, with a median PFS of 2.3, 2.1, 7.5 years, and
unreached for decades 1 to 4, respectively (P < 0.001, Fig. 1a).
In addition, the proportion of patients progressing within
the first 2 years after the initiation of frontline therapy
(early progressors or POD24) significantly decreased over
the decades (44%, 46%, 25%, and 19% for decades 1–4,
















Age, median (range) 57 (23–93) 54 (24–85) 54 (24–88) 57 (23–93) 61 (26–91) <0.001
Female sex (%) 389 (53) 33 (42) 92 (56) 138 (54) 126 (54) NS
Histologic grade 1
or 2 (%)
419 (84) NA 59 (89) 184 (83) 172 (83) NS
ECOG ≥ 2 (%) 64 (9) 16 (21) 18 (11) 15 (6) 15 (7) <0.001
Ann Arbor stage IV (%) 433 (60) 45 (57) 97 (62) 149 (59) 142 (62) NS
Elevated LDH (%) 126 (19) 17 (25) 30 (22) 42 (19) 37 (17) NS
Elevated β2-
microglobulin (%)
241 (43) 4 (57) 45 (36) 80 (37) 112 (52) 0.005
High-risk FLIPI (%) 163 (25) 20 (30) 38 (27) 39 (17) 66 (29) 0.009
CR/CRu (%) 437 (64) 37 (48) 85 (53) 177 (73) 138 (70) <0.001
PR (%) 186 (28) 33 (42) 57 (36) 45 (19) 51 (26)
Refractory disease (%) 54 (8) 8 (10) 18 (11) 19 (8) 9 (4)
Response data are calculated only on the 677 patients of the series who received any treatment. Data concerning β2-microglobulin levels should be interpreted with
caution for decade 1, since only seven patients had available data.
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, FLIPI Follicular Lymphoma International Prognostic Index, NA not available, NS not statistically
significant, CRu complete response unconfirmed, PR partial response.
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Median PFS, years 4.3 2.3 2.1 7.5 NR <0.001
5-year PFS, % 46 40 26 55 56
10-year PFS, % 34 29 14 43 NR
Early progression
(POD24) (%)
204 (30) 34 (44) 73 (46) 60 (25) 37 (19) <0.001
OS
Median OS, years 17.6 12.3 11.8 NR NR <0.001
5-year OS, % 81 77 74 83 86
10-year OS, % 65 52 56 72 –
Histological transformation
5-year risk, % 7 7 9 5 8 NS
10-year risk, % 10 8 15 7 –
Second malignancy
5-year risk, % 5 1 5 7 4 NS
10-year risk, % 10 5 9 12 –
Due to short follow-up for Decade 4, data concerning survival and risk of histological transformation and second malignancies should be interpreted with caution.






Fig. 1 a progression-free survival of the 677 FL patients who received any treatment, according to the decade of diagnosis. b overall survival of the
727 FL patients of the series, according to the decade of diagnosis. D decade, FL follicular lymphoma.
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respectively, P < 0.001). When evaluating survival from an
event-defining timepoint (the time of progression for
POD24 patients, or 2 years of follow-up for non-POD24
patients), no significant differences were noted among
decades, although early progression retained its negative
impact on survival for patients diagnosed in all four
decades (P < 0.0001; Supplementary Fig. 1).
Histological transformation and second malignancies
Risk of HT and SM are plotted in Fig. 2 and Supple-
mentary Fig. 2. HT to diffuse large B-cell lymphoma
(DLBCL) was seen in 13 (17%), 30 (18%), 23 (9%), and 15
(7%) patients diagnosed during decades 1–4, respectively.
For the entire series, the median time to HT was 4.1 years
(range, 3 months–25.8 years). The 5- and 10-year risks of
HT for the entire cohort were 7 and 10%, respectively,
with no significant differences across decades. Likewise,
we did not find significant differences in the rate of HT
according to the frontline exposure of rituximab, with or
without maintenance.
The diagnosis of a second malignancy after the diagnosis
of FL was made in 16 (20%), 37 (23%), 39 (15%), and 10
(4%) patients for those diagnosed during decades 1–4,
respectively. The median time to the development of a SM
was 7.7 years (range, 1 month–33 years), with a 10-year
risk of SM of 10% for all patients, and 5%, 9%, and 12% for
decades 1–3, respectively, with no significant differences
across decades. Hematological malignancies constituted
the most frequent type of SM, which accounted for 20% of
cases, including five cases of acute myeloid leukemia.
Other frequent sites for the development of SM were the
genitourinary tract (17%), the lung and ear, nose, and
throat area (15%), and the skin (non-melanoma skin can-
cer, NMSC, 11%). When the cumulative incidence of SM
was evaluated according to the site (hematological malig-
nancies, solid tumors excluding NMSC, and NMSC alone),
no significant differences were observed across decades.
Likewise, we did not find significant differences in the risk
of SM according to the treatment with fludarabine or stem
cell transplantation (autologous or allogeneic).
Overall and relative survival
Two hundred and sixty-eight patients (37%) eventually
died during the time of follow-up. Median OS for the
entire cohort was 17.6 years, and the 10-year OS rate was
65%. As seen for PFS, there was a significant increase in
OS, the median OS being 12.3 and 11.8 years for decades
1 and 2, respectively, and unreached for decades 3 and 4
(P < 0.001, Fig. 1b). The 10-year OS rate for decades 1 to 4
was 52%, 56%, 72%, and not calculable, respectively.
The outcome of patients along the decades was studied
in terms of relative survival (RS) with respect to the
general Spanish population (Fig. 3, Supplementary Table
4, and Supplementary Fig. 3). As mentioned above, PFS
and OS greatly improved across the decades. This
improvement was substantially more evident for FL
patients than the gains in life expectancy for the sex- and
age-matched general population. Importantly, however,
the diagnosis of FL remained a burden for OS, which was
significantly inferior to the expected survival of the gen-
eral population. The 5-year relative survival ratios (RSR)
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Fig. 2 Risk of histological transformation (HT, a) and of second malignancies (SM, b). D decade.
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respectively. The 10-year RSR were 0.62, 0.64, 0.83, and
not calculable, for decades 1–4, respectively. When
assessing the evolution of RS according to age (less than
50 years, 50–69 years, and 70 years or more) and sex, the
trend of improvement was seen across decades for both
sexes and all three age groups.
Causes of death
The exact cause of death was known for 233 (95.2%) of
the 268 deceased patients. For patients dying within the
10 years of the diagnosis of FL, 61% of those diagnosed in
decade 1 died due to progression of FL, while this per-
centage progressively decreased during the last two dec-
ades (42 and 45% for decades 3 and 4, respectively, P=
0.020, Table 3). Consequently, the percentage of patients
dying from other/unknown causes increased (28 and 35%
for decades 1 and 4, respectively).
Using cumulative incidence of mortality with competing
risk of death, 5-year mortality due to progressive FL was
estimated at 14 and 20% for decades 1 and 2, respectively,
in contrast with 7 and 7% for decades 3 and 4, respectively
(P < 0.0001). Cumulative incidence of death from com-
plications of therapy or that due to other neoplasms was
not significantly different across decades (Fig. 4 and
Supplementary Table 5).
Discussion
In the analysis of our cohort of 727 FL patients, span-
ning almost four decades, we sought to describe variations
in care and outcome. Patients diagnosed during decade 4
were older but had a better performance status. These
trends presumably reflect changes in the reference
population of our institution, and the performance of a









Fig. 3 Relative survival ratios (RSR, calculated by dividing observed by expected survival) are detailed in the built-in tables and color-
coded within each row, red and green representing poorer and better RSR values, respectively. a Comparison of observed (solid line) versus
expected OS (dashed line) for the global series. b Comparison of observed (solid line) versus expected OS (dashed line) according to the decade of
diagnosis. D decade, y year.











Progression of FL (%) 111 (54) 22 (61) 47 (66) 28 (42) 14 (45)
Complications of
therapy (%)
18 (9) 1 (3) 5 (7) 9 (14) 3 (10)
Other neoplasms (%) 31 (15) 3 (8) 9 (13) 16 (24) 3 (10)
Others/unknown (%) 44 (22) 10 (28) 10 (14) 13 (20) 11 (35)
The Others/unknown group is composed of 23 patients (11%) dying of other causes (mainly geriatric complications and cardiovascular disease), and 21 patients (10%)
for whom information concerning the exact cause of death was not available.
FL follicular lymphoma.
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asymptomatic elderly individuals, which might recognize
FL at an older age. No patient received immunotherapy
during decades 1 and 2, being CHOP-like regimens the
most common therapeutic options. With the advent of
rituximab, R-CHOP was the most used first line treatment
(around 40% of patients in decades 3 and 4).
The fraction of patients achieving a CR after frontline
treatment markedly increased over time, likely on account
of the adoption of immunotherapy. However, taking into
account that PET-CT can help consider as a CR a study
where there is a residual mass without metabolic activity,
the advent of this technique cannot be discarded as a
contributing factor to an improvement in observed
responses. This deepening of responses translated into a
better PFS (40–56% at 5 years, for decades 1 and 4,
respectively) and OS (77–86% at 5 years, for decades 1
and 4, respectively), as previously shown by multicenter
studies in the rituximab era23.
Evidences of improvement in PFS and OS in patients
with FL over the last decades have been published in
recent years. Some single-center and registry studies have
shown an improved survival of FL patients with respect to
a sex- and age-matched population7,9. Our series shows
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Fig. 4 Cause-specific cumulative incidence of mortality, using competing risk of death. a death due to progressive FL; b death due to
complications of therapy; c death due to other neoplasms; d death due to other/unknown causes.
Mozas et al. Blood Cancer Journal           (2020) 10:31 Page 7 of 9
Blood Cancer Journal
decade 1 to 0.94 in decade 4 and a 10-year RSR increasing
from 0.62 in decade 1 to 0.83 in decade 3. To evaluate the
causes of death in the present series, we first considered
only patients dying within the first decade after diagnosis,
with the intention of equalizing follow-up among decades.
Although the proportion of patients dying due to pro-
gressive FL has decreased across decades (61–45% from
decades 1–4), most patients still die from lymphoma-
related causes (55% in decade 4, considering progressive
disease and therapy-related complications), in line with
recent results arising from large cohorts24. This fact
underscores the need for new therapies with improved
toxicity profiles and a lower potential to induce SM.
When evaluating causes of death of the entire series using
a cumulative mortality risk analysis with competing cau-
ses of death, we were able to identify a marked reduction
in the cumulative incidence of death due to progressive
disease.
In contrast with recent reports describing a reduced risk
of HT in the rituximab era19, we were not able to identify
significant differences in its incidence among decades,
presumably to the relatively small number of this type of
event in each of the decades. However, HT rates in the
last two decades of the study are superimposable to that
reported in the Aristotle study19.
The appearance of a SM represents one of the concerns
of the use of cytotoxic agents, which has led to a growing
interest in the development of chemotherapy-free regi-
mens. In the rituximab era, its cumulative incidence has
been estimated to be of 2.9% at 10 years for SM arising at
any site24, and of 2.7% at 10 years for second hematolo-
gical malignancies specifically25. In our series, the 10-year
incidence of SM of any site was 10%, with no significant
differences among decades, and hematological malig-
nancies were the most common subtype. Although
follow-up is short, the incidence of SM observed in dec-
ade 4 strongly compares with that reported by Sarkozy
and colleagues24.
We have to acknowledge some limitations of our study.
First, due to short follow-up of patients in decade 4, data
concerning survival and the risk of HT and SM should be
interpreted with caution. Second, baseline characteristics
were not totally uniform among decades. However, the
fact that patients in decade 4 were older might further
underscore the improvement in outcomes of FL patients,
since older individuals would be expected to fare more
poorly. Third, due to historical reasons, the number of
patients in decade 1 was lower, as was the availability of a
diagnostic specimen for histological review, and data
regarding the cause of death, which might explain the
higher percentage of patients dying from other/unknown
causes in this period of time. Fourth, the low number of
patients developing a HT in each decade might hamper
the ability to observe a decreased HT rate in the rituximab
era. Finally, considering the nature of this disease, an
analysis of second and subsequent lines of therapy might
help to better characterize progression/relapse patterns
and outcomes. Among the strengths of the current study,
however, are the large number of patients from a single
institution, diagnosed and treated with comparable stan-
dards within each decade, the high availability of clinical
characteristics and follow-up data, and the use of robust
statistical methods to analyze relative survival and com-
peting risks (HT, SM, and causes of death).
In conclusion, in our series, we observed that FL patients
have experienced an increase in the CR rate after frontline
treatment, with a positive impact on PFS, OS, RS, and
cumulative incidence of death due to progressive FL.
Conversely, the risk of HT and SM, as well as the percen-
tage of lymphoma-related deaths have remained essentially
unchanged, highlighting the need for further advances in
prognostic and therapeutic tools for this disease.
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